Did The 2017 Biosimilar Industry Pave The Way For A Productive 2018?

28 December 2017

Value-added medicines: how repurposed medicines bring value to patients and pharmacists

21 December 2017

Pharmacovigilance, traceability and building trust in biosimilar medicines

21 December 2017

The associations representing the European and British life science industry (AESGP, ABPI, BGMA, BIA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union

14 December 2017

Today, organisations representing the life science industry in the EU […]

European Commission launches: “What I need to know about Biosimilar Medicines – Information for patients”, in 23 EU languages

29 November 2017

The European Commission launched today additional translations of the Q&A […]

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit

28 November 2017

The associations representing the European and British life science industry […]

Medicines for Europe calls for greater cooperation on value added medicines to improve patient-centric innovation

22 November 2017

The 1st Value Added Medicines conference organised by the Value […]

Medicines for Europe welcomes decision on EMA relocation to Amsterdam

21 November 2017

Medicines for Europe is very glad to see the Council […]

Manufacturing cost transparency could combat pricing criticism, says expert

2 November 2017

Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs

18 October 2017

On Thursday 12 October, the Directorate-general for Internal Market, Industry, […]